AIM ImmunoTech Inc (AMEX:AIM)
$ 0.41805 -0.01855 (-4.25%) Market Cap: 21.27 Mil Enterprise Value: 10.63 Mil PE Ratio: 0 PB Ratio: 2.20 GF Score: 41/100

AIM ImmunoTech on Commercial Launch in Argentina for Chronic Fatigue and COVID-19 Clinical Trials- Corporate Analyst Meeting Transcript

Jul 31, 2020 / NTS GMT
Release Date Price: $2.92 (+5.42%)
Robert Kraft
SNN Incorporated - Analyst

This is Robert Kraft, and I'm your host on SNN Network. And joining me right now is Tom Equels. He is the CEO of AIM ImmunoTech. It's publicly traded company. The symbol is AIM on the NYSE American.

Tom, good to have you back. How are you doing?

Tom Equels
AIM ImmunoTech Inc. - CEO

Good to see you, Robert. Always a pleasure.

Questions & Answers

Robert Kraft
SNN Incorporated - Analyst

Always pleasure. So, we last had you on here end of May this year. Now, the companies put out a good amount of news since then. Going through to figure out, I want to I'm going to start with, let's say, the most recent news after our interview, and now the update on the commercial launch of Ampligen in Argentina for the treatment of chronic fatigue syndrome. So can you give us a little more detail there?

Tom Equels
AIM ImmunoTech Inc. - CEO

Yes. With regard to Argentina, we shipped the initial shipments to Argentina of commercial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot